News

Cancer is overtaking cardiovascular disease as a leading cause of death in people with type 2 diabetes. A new paper in Diabetologia looks at trends in cancer mortality in England over a 20-year period and it...

With the increasing use of continuous glucose monitoring (CGM) in people with diabetes, glucose metrics are starting to complement HbA1c in both diabetes care and clinical trials. To reduce the risk of compl...

Cardiovascular disease (CVD) is more common in people with type 1 and type 2 diabetes than among the general population. The increasing global burden of diabetes means that many more people are now at risk o...

The Hypo-RESOLVE consortium is dedicated to developing new tools to investigate the impact of hypos and to find solutions to improve the lives of people with diabetes. New Hypo-RESOLVE studies on the psychos...

Bariatric surgery can put type 2 diabetes into remission, but it’s not without complications, including hypoglycaemia after meals. A new study in Diabetologia sheds some light on the underlying pathoph...

Many people with diabetes would like to reduce the number of insulin injections they need, which is why the development of weekly insulins has been watched with great interest. Findings from recent clinical ...

As rates of type 2 diabetes and prediabetes continue to soar, so too are rates of cardiorenal complications. What can we do to tackle this globally significant health challenge? For the third episode in our ...

Poor glycaemic control before and during pregnancy can increase the risk of congenital malformations and perinatal death among the offspring of women with type 1 diabetes. A new analysis of real-world data, ...

Automated insulin delivery (AID) within hybrid closed loop systems is starting to take centre stage in diabetes management. Findings from recent AID studies in a real-world setting in France, Belgium and Eng...

People’s beliefs about hypoglycaemia were explored as part of the HypoCOMPaSS trial, which aimed to help those with impaired awareness reduce their rate of severe hypos. The findings, reported in a rec...

The wider use of continuous glucose monitoring (CGM) raises questions about the significance of low glucose readings. According to findings presented at the recent Advanced Technologies & Treatments for ...

The risk of progression to clinical diabetes after initial decline in beta cell function depends on age, according to a paper in a recent issue of Diabetologia. The researchers have mapped the trajectory of ...

People with type 2 diabetes often start on non-insulin glucose-lowering medication but, as their condition progresses, they may need insulin. Dr Lalantha Leelarathna, consultant diabetologist at the Manchest...

A new paper in Diabetologia describes how a unique dataset of HbA1c measurements drawn from the UK Biobank reveals the extent of undiagnosed diabetes. The findings suggest that population-wide screening coul...

There are exciting developments in diabetes technology happening right now, which can help lighten the daily burden of managing the condition. The challenge of making the latest diabetes devices and monitori...

As Muslims around the world embark on a month of Ramadan fasting, for the latest episode in our series ‘The long and the short of it’, Professor Wasim Hanif and Dr Sarah Ali deliver a timely remi...

Diabetes in Europe has become a rapidly accelerating public health crisis. That is why the EASD and other major stakeholders have come together to form the European Diabetes Forum, which aims to translate re...

Over the one hundred years since its first use, insulin has undoubtedly saved many lives, yet it still does not fully meet the needs of people living with diabetes. However, there is cause for optimism, acco...

Pregnancies complicated by diabetes are on the increase and pose risks for mother and baby. The role of diabetes technology in improving outcomes in these pregnancies was under discussion at ‘Revolutio...

Suzie Normanton, EASD e-Learning’s Accreditation and Feedback Lead, reports on the feedback we’ve received over recent months – and what’s been done to address it.

SGLT-2 inhibitors and GLP-1 receptor agonists have benefits that go beyond glucose-lowering in diabetes. A new study, reported in Diabetologia, looked at the cost-effectiveness of these medications. The find...